Astrocytoma Market

DelveInsight’s Astrocytoma market report thoroughly explains Astrocytoma, historical and forecasted epidemiology, as well as the Astrocytoma market trends in the 7MM. 

Some of the Key Highlights from the Astrocytoma Market Report

• According to Crocetti et al., astrocytic tumor incidence rates vary significantly among European areas, ranging from 3/100,000 in Eastern Europe to 5/100,000 in the United Kingdom.
• According to the National Organization for Rare Disorders (NORD), Anaplastic astrocytoma and glioblastoma multiforme are expected to affect 5-8 persons per 100,000 in the general population.
• Leading players in the Astrocytoma market include Denovo Biopharma, Orbus Therapeutics, Diffusion Pharmaceuticals, and others.
• Key Astrocytoma therapies in the pipeline include DB102, Eflornithine, Trans Sodium Crocetinate (TSC), and others.
• The US FDA and EMA designated DB102 (Denovo Biopharma) as an orphan drug for DLBCL and glioblastoma multiforme (GBM), and the US FDA granted it Fast Track Designation.

Have queries? Request for the sample @ Astrocytoma Market Outlook

Astrocytoma Overview

Astrocytoma is a tumor that can develop in the brain or the spinal cord. It starts in nerve-supporting cells called astrocytes and is the most frequent type of brain tumor in adults. Astrocytoma is classified as grade 1 (most benign) to grade 4 (most malignant) by the World Health Organization (WHO).

Astrocytoma Epidemiology Segmentation

The Astrocytoma report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into: 

• Astrocytoma Total Incident Cases 
• Astrocytoma Grade-Specific Cases 
• Astrocytoma Total Diagnosed Cases 
• Astrocytoma Gender-Specific Cases 
• Astrocytoma Line Wise Treated Cases 

Astrocytoma Treatment Landscape

The current Astrocytoma treatment options include:

• Surgery
• Steroids
• Chemotherapy
• Radiotherapy
• Bevacizumab (Avastin)
• Off Label Therapies (Procarbazine hydrochloride)

Astrocytoma Market Outlook

The Astrocytoma market will expand during the forecast period, 2021–2030, due to an increase in the incidence of brain tumors and the anticipated launch of novel therapies such as  DB102, Eflornithine, Trans Sodium Crocetinate (TSC), and others.

Discover more about the future market share of the drugs @ Astrocytoma Market Analysis

Astrocytoma Pipeline Therapies and Key Companies 

•  DB102: Denovo Biopharma
• Eflornithine: Orbus Therapeutics
• Trans Sodium Crocetinate (TSC): Diffusion Pharmaceuticals

Table of Contents 

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Anaplastic Astrocytoma Market

DelveInsight’s “Anaplastic Astrocytoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Anaplastic Astrocytoma, historical and forecasted epidemiology as well as the Anaplastic Astrocytoma market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/